Clinical trial NCT05248802: DLBS2411 Treatment For Functional Dyspepsia
Official title: Randomized Controlled Trial of DLBS2411 Treatment For Functional Dyspepsia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Functional Dyspepsia
Keywords: Functional Dyspepsia
DLBS2411
Epigastric Pain Syndrome
Postprandial Distress Syndrome
Lead sponsor: Dexa Medica Group
Sponsor class: INDUSTRY
First posted: 2022-02-21
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit.

The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. The mechanism altogether demonstrated DLBS2411's protective capacity to the gastric and colon mucosa by promoting mucous synthesis and stimulating mucosal blood flow.

Having such mechanisms of action, DLBS2411 is hypothesized to benefit subjects with gastric acid disorders such as in functional dyspepsia, gastro-intestinal reflux disease (GERD), peptic-ulcer, and irritable bowel syndrome (IBS).

Detailed description: Study population will be patients with functional dyspepsia (FD) who come to the study site. There will be 100 subjects (50 subjects in each group) planned to be enrolled in the study.

There will be 2 groups of treatment; Treatment 1: placebo DLBS2411 caplet Treatment 2: DLBS2411 250 mg caplet Each study medication will be administered 1 caplet twice daily, 30 minutes before meal, in the morning and evening.

Eligible subjects will be randomly allocated to receive either Treatment 1 or Treatment 2 for 4 weeks, in a double blind fashion. Subjects will be instructed to come to the clinic every 2-week interval throughout the 4-week study period (at Week 2, and 4, respectively) and 8 weeks after the end of therapy (Week 12), for efficacy evaluation. The safety evaluation will be performed at Baseline and End of therapy (Week 4). Adverse events will be monitored at baseline and every follow-up visit including End of study (Week 12).

Eligibility criteria: Key Inclusion Criteria:

1. Signed informed consent prior to participation in the study.
2. Male or female subjects aged of 18 - 75 years old.
3. Meet Rome IV criteria for FD, which includes:

   1. One or more of the following symptoms:

      * bothersome postprandial fullness
      * early satiation, that prevents finishing a regular meal, at least several times per week.
      * epigastric pain, epigastric burning. The symptoms are persistently present (i.e. occurring at least one day per month (for male) or 2-3 days per month (for female) for at least the past 3 months with symptom onset at least 6 months prior to study Screening.
   2. Having no evidence of structural or organic gastrointestinal (GI) disease that is likely to explain the symptoms, as verified by a normal esophagogastroduodenoscopy (EGD) performed within the past 3 years.
4. Subjects who tested negative for Helicobacter pylori by urea breath-test, histological or rapid test during the screening period.
5. Able to take oral medication.

Key Exclusion Criteria:

1. Pregnancy, breast-feeding females.
2. Subjects suspected COVID-19 by clinical symptoms and rapid antigen test (reactive result) for SARS-COV-2.
3. GERD as confirmed by any documented history of endoscopic esophagitis, or clinical symptoms such as predominant heartburn or acid regurgitation, \>2x/week in the prior year.
4. History of or known or suspected Zollinger Ellison syndrome.
5. History of or known gastrointestinal malignancy or ulcers associated to malignancy.
6. Hepatic cirrhosis or abnormal liver laboratory findings (defined as \>3xULN of ALT or AST).
7. Being under hemodialysis therapy or having advanced chronic kidney disease (defined as eGFR \<60 mL/min).
8. History of or known congestive heart failure NYHA class III and IV, or any other uncontrolled chronic diseases, such as: uncontrolled hypertension (systolic/diastolic blood pressure ≥160/100 mmHg); uncontrolled diabetes (HbA1c c ≥7%).
9. Currently known being afflicted by serious infection(s), or any known severe illness(es) which are judged by the Investigator could interfere with subjects' safety and/or study evaluation.
10. Taking medication affecting the gastrointestinal system within 2 weeks prior to Screening, such as: prokinetics, acid release inhibitors (histamine-2-receptor \[H2\]- antagonists, proton pump inhibitors \[PPI\], or potassium-competitive acid blockers), gastric mucosa protectors (sucralfate, rebamipide), and any gastric-relevant herbal medicines.
11. Participation in any other clinical studies within 30 days prior to Screening.

Primary outcomes:
measure: Short-Form Nepean Dyspepsia Index (SF-NDI)
timeFrame: Week 4
Secondary outcomes:
measure: Short-Form Nepean Dyspepsia Index (SF-NDI)
timeFrame: Week 2 and 12
measure: Visual Analogue Scale (VAS)
timeFrame: Week 2, 4, and 12
measure: The proportion of subjects reaching adequate / satisfactory relief from FD symptoms
timeFrame: Week 2, 4, and 12
measure: Number of adverse event during the study
timeFrame: Week 2, 4, and 12
Other outcomes:
Locations:
city: Semarang
country: Indonesia
facility: Department of Internal Medicine, Dr. Kariadi General Hospital
state: Central Java
city: Sukoharjo
country: Indonesia
facility: Department of Internal Medicine, Universitas Sebelas Maret (UNS) Hospital
state: Central Java
city: Surakarta
country: Indonesia
facility: Department of Internal Medicine, Dr. Moewardi Hospital
state: Central Java
city: Jakarta
country: Indonesia
facility: Department of Internal Medicine, Budhi Asih Hospital
state: DKI Jakarta
city: Jakarta
country: Indonesia
facility: Department of Internal Medicine, Fatmawati General Hospital
state: DKI Jakarta
city: Jakarta
country: Indonesia
facility: Department of Internal Medicine, Pasar Rebo Hospital
state: DKI Jakarta
city: Surabaya
country: Indonesia
facility: Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
state: Jawa Timur
city: Jakarta
country: Indonesia
facility: Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital
Study officials:
affiliation: Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital, Jakarta Indonesia
name: Ari F Syam, Prof, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Budhi Asih Hospital, East Jakarta, Indonesia
name: Agasjtya W Wardhana, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Pasar Rebo Hospital, South Jakarta, Indonesia
name: Nugroho B Santoso, MD, Sp.PD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Dr. Kariadi General Hospital, Semarang, Indonesia
name: Hery D Purnomo, Dr, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Dr. Moewardi Hospital, Surakarta, Indonesia
name: Triyanta Y Pramana, Dr, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Fatmawati General Hospital, Jakarta,
name: Mulyana Edi, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine Universitas Sebelas Maret (UNS) Hospital, Sukoharjo, Indonesia
name: Coana Sukmagautama, MD, Sp.PD, M.Kes.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
name: Ulfa Kholili, MD, Sp.PD-KGEH
role: PRINCIPAL_INVESTIGATOR
References: